These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 18077527)

  • 21. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.
    Kasamon YL; Wahl RL
    Curr Opin Oncol; 2008 Mar; 20(2):206-19. PubMed ID: 18300772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG PET in children with lymphomas.
    Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
    Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
    Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.
    Zijlstra JM; Lindauer-van der Werf G; Hoekstra OS; Hooft L; Riphagen II; Huijgens PC
    Haematologica; 2006 Apr; 91(4):522-9. PubMed ID: 16585017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of
    Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
    Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
    Pakos EE; Fotopoulos AD; Ioannidis JP
    J Nucl Med; 2005 Jun; 46(6):958-63. PubMed ID: 15937306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
    Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
    ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
    Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
    J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
    Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
    Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
    García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease.
    Poulou LS; Karianakis G; Ziakas PD
    Eur J Radiol; 2009 Jun; 70(3):499-506. PubMed ID: 18342471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
    Araf S; Montoto S
    Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.